Astellas Pharma (OTCMKTS:ALPMY) Posts Earnings Results, Beats Expectations By $0.15 EPS

Astellas Pharma (OTCMKTS:ALPMY) issued its quarterly earnings results on Monday. The company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.15, Zacks reports. The business had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.28 billion. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%.

Astellas Pharma Stock Down 4.6%

ALPMY stock opened at $14.41 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84. Astellas Pharma has a 1-year low of $8.97 and a 1-year high of $17.35. The firm has a fifty day moving average price of $15.76 and a two-hundred day moving average price of $13.99. The firm has a market cap of $26.08 billion, a price-to-earnings ratio of 13.47 and a beta of 0.17.

Analyst Ratings Changes

A number of brokerages recently issued reports on ALPMY. Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Citigroup lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 19th. Zacks Research upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Friday, April 24th. Finally, Smbc Nikko Sec. upgraded shares of Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. Two analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Astellas Pharma presently has an average rating of “Moderate Buy”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).